Prometrium and Simvastatin Interaction: What Patients and Prescribers Need to Know

Does Prometrium Interact With Simvastatin?

Prometrium (micronized progesterone 100 mg or 200 mg capsules) and simvastatin do interact through the CYP3A4 enzyme system. Progesterone acts as a competitive inhibitor of CYP3A4 at concentrations achieved after oral dosing, while simvastatin depends on CYP3A4 for first-pass and systemic metabolism. Reduced CYP3A4 activity means simvastatin clears more slowly, raising active drug and active metabolite levels in plasma.

The FDA-approved prescribing information for simvastatin lists CYP3A4 inhibition as the central mechanism behind its most serious drug interactions, and the label specifically states that simvastatin exposure increases substantially when CYP3A4 is blocked. [1] The Prometrium prescribing information acknowledges CYP3A4 as a primary metabolic route for micronized progesterone and notes the potential for bidirectional interactions with other CYP3A4-active compounds. [2]

How Common Is This Clinical Scenario?

Postmenopausal women represent the largest group receiving Prometrium for endometrial protection during hormone therapy. The same population carries elevated cardiovascular risk and is frequently prescribed statins. Data from the Women's Health Initiative showed that more than 30% of women enrolled were taking lipid-lowering therapy at baseline. [3] Simvastatin has historically been one of the most dispensed statins in the United States, meaning overlap between HRT users and simvastatin users is common in clinical practice.

The CYP3A4 Mechanism in Detail

Progesterone as a CYP3A4 Inhibitor

Progesterone and its metabolites bind to the active site of CYP3A4, reducing the enzyme's capacity to oxidize co-administered substrates. A 2003 in vitro study published in Drug Metabolism and Disposition demonstrated that progesterone inhibits CYP3A4-mediated testosterone 6-beta-hydroxylation with a Ki in the low-micromolar range, a concentration consistent with peak plasma levels after a 200 mg oral dose of Prometrium. [4] This inhibition is competitive rather than mechanism-based, meaning it is concentration-dependent and partially reversible as progesterone levels fall.

Simvastatin's Dependence on CYP3A4

Simvastatin is a lactone prodrug converted by intestinal and hepatic CYP3A4 to simvastatin acid, the pharmacologically active HMG-CoA reductase inhibitor. When CYP3A4 is inhibited, simvastatin acid accumulates. A controlled pharmacokinetic study by Kantola et al. (1998) showed that itraconazole, a potent CYP3A4 inhibitor, increased simvastatin AUC by approximately 19-fold. [5] Progesterone is a moderate rather than potent inhibitor, so the magnitude of interaction is smaller, but the directional risk is the same: higher simvastatin acid exposure and greater potential for skeletal muscle toxicity.

P-glycoprotein: A Secondary Pathway

Simvastatin is also a substrate of P-glycoprotein (P-gp), an efflux transporter that limits intestinal absorption and hepatic uptake of many drugs. Progesterone has been identified as a P-gp inhibitor in cell-based assays, suggesting an additive mechanism beyond CYP3A4 alone. [6] The clinical magnitude of P-gp inhibition by progesterone at therapeutic doses is less well characterized than the CYP3A4 effect, but it provides a secondary rationale for monitoring.

Severity Classification and Clinical Risk

Myopathy and Rhabdomyolysis Risk

Statin-associated myopathy is dose-dependent. The SEARCH trial (N=12,064) found that simvastatin 80 mg/day produced myopathy in 0.9% of patients compared with 0.03% in the 20 mg group, a 30-fold difference tied directly to drug exposure. [7] Any pharmacokinetic interaction that raises simvastatin exposure effectively moves patients toward a higher functional dose even without a prescription change. Rhabdomyolysis, the severe end of the myopathy spectrum, can cause acute kidney injury and carries a case fatality rate of approximately 10% when complicated by renal failure. [8]

How Pharmacovigilance Databases Classify This Pair

The FDA Adverse Event Reporting System (FAERS) and clinical decision-support tools such as Lexicomp and Micromedex generally classify the progesterone-simvastatin interaction as moderate severity. The FDA simvastatin label, last revised with major interaction warnings, explicitly states: "Simvastatin, like other HMG-CoA reductase inhibitors, is a substrate of CYP3A4. Large increases in simvastatin exposure are associated with increased risk of myopathy, including rhabdomyolysis." [1] Because progesterone is a moderate rather than strong inhibitor, the label does not list it among contraindicated combinations (which include itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone), but clinical caution is still warranted.

Risk Stratification by Simvastatin Dose

| Simvastatin Dose | Baseline Myopathy Risk | Risk With Moderate CYP3A4 Inhibitor | |---|---|---| | 10 mg/day | Low | Low-moderate | | 20 mg/day | Low-moderate | Moderate | | 40 mg/day | Moderate | Moderate-high | | 80 mg/day | High (restricted use) | High; avoid combination |

Clinicians should treat the 80 mg simvastatin dose as effectively contraindicated whenever a CYP3A4 inhibitor, including Prometrium, is being added. The FDA restricted simvastatin 80 mg to patients already tolerating it for 12 or more months without myopathy, precisely because of dose-related toxicity concerns. [1]

Monitoring Protocol

Before Starting Prometrium in a Simvastatin User

A structured pre-treatment review should include four steps:

1. Record current simvastatin dose and duration of therapy.
2. Obtain a baseline creatine kinase (CK) level and alanine aminotransferase (ALT).
3. Ask about any current muscle symptoms: aches, weakness, or brown urine.
4. Document kidney function (serum creatinine or eGFR), because impaired clearance amplifies statin toxicity independently. [9]

If the patient is on simvastatin 80 mg, consult with the prescribing cardiologist or internist before starting Prometrium. Consider switching to a non-CYP3A4 statin at this point rather than layering an inhibitor onto an already high-risk dose.

After Starting Prometrium

Repeat CK and ALT at 4 to 6 weeks after Prometrium initiation. Counsel patients to report muscle pain, unexplained fatigue, or dark urine immediately rather than waiting for a scheduled visit. A CK elevation greater than 10 times the upper limit of normal, or any CK elevation accompanied by symptoms, meets the threshold for stopping simvastatin and evaluating for rhabdomyolysis. [9]

Ongoing Surveillance

Once stable on the combination, annual CK monitoring is reasonable in the absence of symptoms. Patients starting any new CYP3A4 inhibitor (an azole antifungal, a macrolide antibiotic, or a calcium-channel blocker such as diltiazem) while already on both Prometrium and simvastatin should be re-evaluated, because additive inhibition can tip a manageable interaction into a clinically significant one.

Dose Adjustment Strategies

Simvastatin Dose Reduction

For patients on simvastatin 40 mg or 80 mg who require Prometrium, a dose reduction to 20 mg or less is the most direct mitigation strategy. The 2022 ACC/AHA cholesterol guideline notes that switching to an equally potent, non-interacting statin is preferable to dose reduction when the interaction involves a persistent CYP3A4 inhibitor. [10]

Switching to a Non-CYP3A4 Statin

Pravastatin undergoes sulfation and glucuronidation rather than CYP3A4 oxidation. Rosuvastatin is metabolized primarily by CYP2C9 and is minimally affected by CYP3A4 inhibitors. Fluvastatin also relies on CYP2C9. Any of these three statins provides LDL-lowering efficacy without the CYP3A4 overlap that creates risk in the Prometrium-simvastatin pair.

Comparative effectiveness data from a 2016 Cochrane review (31 randomized trials, N over 27,000) confirmed that rosuvastatin 10 to 20 mg and atorvastatin 20 to 40 mg produce LDL reductions equivalent to simvastatin 40 to 80 mg, supporting the clinical practicality of switching. [11]

Prometrium Dose Timing

Prometrium is typically dosed at bedtime, which produces peak plasma progesterone concentrations in the early morning hours when simvastatin doses (usually taken in the evening) are already declining. Whether this temporal offset meaningfully reduces CYP3A4 inhibition overlap has not been studied in a controlled pharmacokinetic trial. Clinicians should not rely on timing alone as a safety measure when higher simvastatin doses are involved.

Patient Counseling Points

The following framework structures the conversation a prescriber or pharmacist should have with a patient starting Prometrium while already on simvastatin.

Explain the mechanism simply. Tell the patient that Prometrium slows the breakdown of simvastatin, which can raise simvastatin levels in the blood. Higher blood levels mean a higher chance of muscle side effects.

Name the specific warning signs. Muscle pain, muscle weakness, or dark brown urine that looks like cola are the three symptoms that require same-day contact with a provider. These can be early signs of rhabdomyolysis, a rare but serious muscle breakdown condition.

Reinforce the monitoring plan. Patients should know a blood test is scheduled for 4 to 6 weeks after starting Prometrium. Missing that follow-up removes the safety net.

Address reassurance without dismissal. The combination is used safely in many patients. Serious adverse events are uncommon when simvastatin doses are 20 mg or below and CK is monitored. The goal is vigilance, not alarm.

Document the counseling. A brief note in the chart confirming the patient understood the interaction, the monitoring plan, and the symptom warning signs provides both clinical and medicolegal clarity.

Special Populations

Women With Hypothyroidism

Hypothyroidism independently raises statin myopathy risk by reducing muscle metabolism. A 2019 analysis in the Journal of Clinical Lipidology found that hypothyroid patients had a 2.5-fold higher rate of statin-related myalgia compared with euthyroid controls at equivalent statin doses. [12] Postmenopausal women on HRT who also have subclinical or overt hypothyroidism represent a high-risk subgroup requiring particularly close CK monitoring when simvastatin is in the regimen.

Renal Impairment

Simvastatin acid is cleared partly by the kidneys. The FDA label recommends caution when simvastatin is used in patients with severe renal impairment (eGFR <30 mL/min per 1.73 m²), suggesting starting at 5 mg/day and monitoring carefully. [1] Adding a CYP3A4 inhibitor on top of renal impairment creates a compounding effect on drug exposure.

Older Adults

Women aged 65 and above have reduced CYP3A4 enzyme activity at baseline and lower muscle mass. Both factors amplify statin myopathy risk independent of any drug interaction. The American Geriatrics Society Beers Criteria recommend against high-dose simvastatin in older adults without careful justification. [13] This population warrants the lowest effective statin dose and the most proactive switch to a non-CYP3A4 agent when Prometrium is introduced.

Comparing Prometrium to Synthetic Progestins

Not all progestins carry the same interaction risk. Medroxyprogesterone acetate (MPA), the most widely used synthetic progestin, is also a CYP3A4 substrate and has been shown to inhibit CYP3A4 activity in vitro. [14] Norethindrone acetate follows a similar metabolic route. By contrast, dydrogesterone (not currently FDA-approved in the United States but used in Europe) shows weaker CYP3A4 affinity.

Micronized progesterone (Prometrium) is often selected in preference to MPA because of its better cardiovascular and breast safety profile based on the E3N cohort study (N=80,377), which found no excess breast cancer risk with micronized progesterone over 5 years compared with a statistically significant increase with synthetic progestins. [15] Switching from Prometrium to MPA to theoretically reduce the simvastatin interaction is therefore not a rational trade-off; the cardiovascular and oncologic risks of MPA likely outweigh a moderate pharmacokinetic interaction that can be managed through statin dose adjustment or substitution.

When the Combination Is Acceptable Without Statin Change

At simvastatin 10 mg to 20 mg per day in a patient with no baseline muscle symptoms, normal CK, and normal renal function, co-prescribing Prometrium at standard doses (100 to 200 mg nightly) carries a low absolute risk of serious adverse events. The 2023 Endocrine Society Clinical Practice Guideline on menopause hormone therapy does not list simvastatin as a contraindication to Prometrium use, and its authors note that cardiovascular risk management should proceed in parallel with HRT without unnecessary interruption of either therapy. [16]

The prescriber's judgment turns on three variables: simvastatin dose, baseline CK and renal function, and patient-specific risk factors for myopathy. When all three are favorable, the interaction is manageable with monitoring rather than requiring a mandatory statin switch.